spacing-lg
Select Clinical Trials in RAS Mutant Cancer
We have a number of clinical trials evaluating investigational RAS(ON) inhibitors.
RASolute 304
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Active, RECRUITING
3 (open-label)
Pancreatic ductal adenocarcinoma (PDAC)
3
RASolve 301
Phase 3 Multicenter, Open Label, Randomized Study of Daraxonrasib (RMC‑6236) Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] Non-Small Cell Lung Cancer (NSCLC)
Active, RECRUITING
3 (open-label)
Non-small cell lung cancer (NSCLC)
3
RASolute 302
Phase 3 Study of Daraxonrasib (RMC‑6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)
Active, NOT RECRUITING
3 (open-label)
Pancreatic ductal adenocarcinoma (PDAC), pancreatic cancer
3
RMC-LUNG-101
Study of RAS(ON) Inhibitor Combination or Monotherapy in Patients With Advanced RAS-mutated NSCLC
Active, RECRUITING
1b/2 (open-label)
Non-small cell lung cancer (NSCLC); KRAS, NRAS, HRAS mutant NSCLC; KRAS G12C mutant solid tumors, lung cancer; lung cancer stage IV, advanced solid tumor, cancer; RAS G12D mutant NSCLC
2
RMC-APEX-103
Study of Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) in Combination With Ivonescimab in Participants With Advanced or Metastatic RAS Mutant Solid Tumors
Active, RECRUITING
1/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), advanced solid tumors, metastatic solid tumors
2
RMC-5127-001
Study of RMC-5127 as Monotherapy and in Combination With Daraxonrasib (RMC-6236) or Cetuximab in Participants With Advanced KRAS G12V Mutant Solid Tumors
Active, RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-9805-001
Study of Zoldonrasib (RMC-9805) in Participants With KRAS G12D Mutant Solid Tumors
Active, RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-GI-102
Study of RAS(ON) inhibitors in Patients With Gastrointestinal Solid Tumors
Active, RECRUITING
1/2 (open-label)
Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), gastrointestinal cancer
2
RMC-6291-101
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C Mutant Solid Tumors
Active, RECRUITING
1b/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC)
2
RMC-6291-001
Dose Escalation and Dose Expansion Study of Elironrasib (RMC-6291) Monotherapy in Subjects With Advanced KRAS G12C Mutant Solid Tumors
Active, NOT RECRUITING
1/1b (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
1
RMC-6236-001
Study of Daraxonrasib (RMC-6236) in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Active, RECRUITING
1/2 (open-label)
Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors
2
All RAS(ON) inhibitors discussed here are investigational. Efficacy and safety have not been established.
Discover all our active clinical trials in the complete list available here: ClinicalTrials.gov.
For questions on our clinical trials, please reach out to medinfo@revmed.com or 1-844-2-REVMED (1-844-273-8633).
spacing-lg